期刊文献+

多发性骨髓瘤肾损伤中IL-6的作用研究

Study on role of IL-6 protein in multiple myeloma nephropathy
原文传递
导出
摘要 目的:研究多发性骨髓瘤(MM)患者中IL-6的表达水平,阐明其在MM肾损伤中的作用及临床意义。方法:采用化学发光法对80例MM肾损伤患者(32例肾功能不全不可逆者,28例肾功能不全可逆者和20例肾功能正常者)以及40例健康体检者的IL-6表达量检测并进行比较。结果:IL-6在肾功能不全不可逆者表达明显升高,与肾功能不全可逆者和MM肾功能正常者以及40例健康体检者IL-6表达比较差异有统计学意义(P<0.01);肾功能不全可逆者和MM肾功能正常者以及40例健康体检者彼此之间IL-6表达比较差异无统计学意义(P>0.05);MM患者不同分期IL-6表达差异有统计学意义(P<0.05)。结论:IL-6检测可作为MM患者肾功能不全病变程度诊断指标,为临床治疗提供帮助。 Objective:To investigate the expressions of IL-6 protein in multiple myeloma nephropathy and their clinical significance. Method:Serum IL-6 levels of 60 cases MM with renal inadequacy, 20 cases MM with normal renal function and 40 healthy people were detected by chemiluminescence assay. Result: II7-6 protein level in con trol was lower than that in multiple myeloma nephropathy. There were statistical significance between the MM with renal inadequacy group and MM with normal renal function(P〈0.01 ). The expressions of II.-6 protein in MM were correlated with Durie-salmon stages(P〈0.05). Conclusion : Detection of II76 protein could be applied in the diagnosis of multiple myeloma nephropathy to help treat the disease.
出处 《临床血液学杂志(输血与检验)》 CAS 2012年第1期84-85,共2页 Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
关键词 多发性骨髓瘤 白细胞介素6 肾损伤 interleukin-6 multiple myeloma nephropathy
  • 相关文献

参考文献4

  • 1KNOBLOCH J, SHAUGHNESSY J, RTITHER U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway[J]. FASEB J,2007,21:1410-1421.
  • 2SCHMIDT-WOLF A, GLASMACHER C, HAHN A, et al. Chrom osomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance[J]. Cancer Genet Cytogenet, 2006,167 : 20-- 25.
  • 3CHANG H, XIAOYING Q, JOANNA YEUNG, et al. Genetic aberrations including chromosome abnor- malities and clinical leatures of plasma cell leukemia [J]. Leuk Res,2008,27:3126--3130.
  • 4周振海,李幼姬.多发性骨髓瘤肾损害发病机制[J].国外医学(内科学分册),2004,31(1):16-20. 被引量:11

二级参考文献23

  • 1Irish AB. Winearls CG, Littlewood T. [J]. QJM. 1997,90( 12 ) :773-780.
  • 2Sakhuja V,Jha V,Varma S.et al. [J]. Ren Fail, 2000.22 ( 4 ) : 465-477.
  • 3Knudsen LM. [J]. Eur J Haematol.1995,53( 1 ) :107.
  • 4Paul KW. John H, Galla A. [J]. Kidney Intrn, 1987,32( 3 ) :851-861.
  • 5Paul W, Sanders S, Guillermo A, et al. [ J ]. Kidney Int, 1998,33 ( 3 ) : 881-889.
  • 6Matsuura K,Ikoma S,Watanabe M, et al. [J]. Immunology, 1999,98 ( 4 ) : 584-589.
  • 7Guan S, El-Dahr S, Dipp S, et al. [ J]. J Investig Med, 1999,47 ( 4 ) : 496-501.
  • 8Pote A,Zwizinski C,Simon E,et al. [J]. Am J Kidney Dis.2000,36(4 ) : 125-131.
  • 9Huang ZQ,Kink K,Kevin G,et al. [J]. J Clin Invest, 1993,92 ( 12 ) : 2975-2983.
  • 10Huang ZQ,Sanders PN. [J]. J Clin Invest, 1997,99(4) :732-760.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部